Clinical Trial Update: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating afatinib followed by osimertinib versus osimertinib alone in EGFR-mutated, T790M mutation-negative non-squamous NSCLC, focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gilotrif (Afatinib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Michael Hopp | Conditions: Non-squamous NSCLC | Phase 4 | Status: ACTIVE_NOT_RECRUITING